GDF2 and fatty liver disease: Yang et al. infected HepG2 cells and mouse primary hepatocytes with either Ad-BMP9 or Ad-GFP and found that Ad-BMP9 treatment could decreased body weight, food intake and liver weight/body weight, decrease liver steatosis, inhibited the expression of genes related to fatty acid synthesis (Yang et al., 2019).